GLP-1 receptor agonists linked to lower mortality for patients with brain metastases, T2DM

For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with significantly lower all-cause mortality, according to a research letter published online March 11 in JAMA Network Open.
Kuan-Yu Chi, M.D., from the Albert Einstein College of Medicine in Bronx, New York, and colleagues conducted a retrospective cohort study to examine the association between GLP-1 RA use and survival among patients with BM and T2D. The exposed cohort included adult patients prescribed GLP-1 RAs within six months before the first instance of T2D and BM diagnosis, while the control cohort had no GLP-1 RA use during the same period.
After propensity score matching, a total of 850 GLP-1 RA users were matched to nonusers among a total of 19,234 patients with cancer, BM, and T2D. The researchers found that all-cause mortality was significantly lower in association with GLP-1 RA use (hazard ratio, 0.63). The observed mortality benefit was consistent across major cancer types and GLP-1 RA types, apart from liraglutide, and compared with other antidiabetes therapies.
“These results build upon existing evidence that GLP-1 receptor activation modulates pathways relevant to neuro-oncologic health, including attenuation of neuroinflammation, preservation of blood-brain barrier integrity, and reduction of oxidative stress and mitochondrial dysfunction,” the authors write.
Publication details
Kuan-Yu Chi et al, GLP-1 Receptor Agonist Use and Survival Among Patients With Type 2 Diabetes and Brain Metastases, JAMA Network Open (2026). DOI: 10.1001/jamanetworkopen.2026.1311
Journal information:
JAMA Network Open
Key medical concepts
GLP-1 Receptor Agonist [EPC]Brain MetastaseDiabetes Type 2All-Cause MortalityNeuroinflammations
Clinical categories
Copyright © 2026 HealthDay. All rights reserved.
GLP-1 receptor agonists linked to lower mortality for patients with brain metastases, T2DM (2026, March 13)
retrieved 13 March 2026
from https://medicalxpress.com/news/2026-03-glp-receptor-agonists-linked-mortality.html
part may be reproduced without the written permission. The content is provided for information purposes only.
📰 This article was curated and published by
HEALTH GUIDANCE HUB
— your trusted source for the latest health news, medical research, and wellness guidance.
Visit us at https://healthguidancehub.space/ for more health insights.

